{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:52:37Z","timestamp":1790689957203,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12272-025-01574-w","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:52:43Z","timestamp":1761828763000},"page":"1299-1313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Resmetirom, the first FDA-approved drug for MASH: From drug discovery and action mechanisms to clinical trials"],"prefix":"10.1007","volume":"48","author":[{"given":"Jiaman","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-3148","authenticated-orcid":false,"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"1574_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/meg.0000000000002901","volume":"37","author":"L Abbasi","year":"2025","unstructured":"Abbasi L, Irfan Q, Zaidi SMM, Jawed I, Malik A, Kaleem S (2025) Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 37:395\u2013402. https:\/\/doi.org\/10.1097\/meg.0000000000002901","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1574_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16220","volume":"45","author":"I Alabdul Razzak","year":"2025","unstructured":"Alabdul Razzak I, Fares A, Stine JG, Trivedi HD (2025) The role of exercise in steatotic liver diseases: an updated perspective. Liver Int 45:e16220. https:\/\/doi.org\/10.1111\/liv.16220","journal-title":"Liver Int"},{"key":"1574_CR3","doi-asserted-by":"publisher","unstructured":"Alkhouri N and Noureddin M 2024 Management strategies for metabolic dysfunction-associated steatotic liver disease. Am J Manag Care. https:\/\/doi.org\/10.37765\/ajmc.2024.89635","DOI":"10.37765\/ajmc.2024.89635"},{"key":"1574_CR4","unstructured":"Alonso-Merino E, Mart\u00edn Orozco R, Ru\u00edz-Llorente L, Mart\u00ednez-Iglesias OA, Velasco-Mart\u00edn JP, Montero-Pedrazuela A, Fanffig"},{"key":"1574_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejim.2024.01.005","volume":"122","author":"A Armandi","year":"2024","unstructured":"Armandi A, Bugianesi E (2024) Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. Eur J Intern Med 122:20\u201327. https:\/\/doi.org\/10.1016\/j.ejim.2024.01.005","journal-title":"Eur J Intern Med"},{"key":"1574_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108811","volume":"268","author":"K Arvanitakis","year":"2025","unstructured":"Arvanitakis K, Koufakis T, Cholongitas E, Francque S, Germanidis G (2025) Insights into the results of resmetirom trials: can a thyroid hormone receptor agonist be the holy grail of MASH therapy? Pharmacol Ther 268:108811. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108811","journal-title":"Pharmacol Ther"},{"key":"1574_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00582-z","author":"K Au","year":"2024","unstructured":"Au K, Zheng MH, Lee WJ, Ghanem OM, Mahawar K, Shabbir A, Le Roux CW, Targher G, Byrne CD, Yilmaz Y, Valenti L, Sebastiani G, Treeprasertsuk S, Hui HX, Sakran N, Neto MG, Kermansaravi M, Kow L, Seki Y, Tham KW, Dang J, Cohen RV, Stier C, Alsabah S, Oviedo RJ, Chiappetta S, Parmar C, Yang W (2024) Resmetirom and metabolic dysfunction-associated steatohepatitis: perspectives on multidisciplinary management from global healthcare professionals. Curr Obes Rep. https:\/\/doi.org\/10.1007\/s13679-024-00582-z","journal-title":"Curr Obes Rep"},{"key":"1574_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"I Ayada","year":"2023","unstructured":"Ayada I, Van Kleef LA, Zhang H, Liu K, Li P, Abozaid YJ, Lavrijsen M, Janssen HLA, Van Der Laan LJW, Ghanbari M, Peppelenbosch MP, Zheng MH, De Knegt RJ, Pan Q (2023) Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine 87:104392. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104392","journal-title":"EBioMedicine"},{"key":"1574_CR9","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","volume":"29","author":"DL Bhatt","year":"2023","unstructured":"Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP (2023) The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat Med 29:1782\u20131792. https:\/\/doi.org\/10.1038\/s41591-023-02427-z","journal-title":"Nat Med"},{"key":"1574_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/hep.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR (2025) Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance. Hepatology 81:312\u2013320. https:\/\/doi.org\/10.1097\/hep.0000000000001112","journal-title":"Hepatology"},{"key":"1574_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12944-022-01730-x","volume":"21","author":"X Chu","year":"2022","unstructured":"Chu X, Zhou Y, Zhang S, Liu S, Li G, Xin Y (2022) Chaetomorpha linum polysaccharides alleviate NAFLD in mice by enhancing the PPAR\u03b1\/CPT-1\/MCAD signaling. Lipids Health Dis 21:140. https:\/\/doi.org\/10.1186\/s12944-022-01730-x","journal-title":"Lipids Health Dis"},{"key":"1574_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","volume":"24","author":"A Do","year":"2025","unstructured":"Do A, Zahrawi F, Mehal WZ (2025) Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov 24:171\u2013189. https:\/\/doi.org\/10.1038\/s41573-024-01084-2","journal-title":"Nat Rev Drug Discov"},{"key":"1574_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.eprac.2024.04.016","volume":"30","author":"D Dutta","year":"2024","unstructured":"Dutta D, Kamrul-Hasan ABM, Mondal E, Nagendra L, Joshi A, Bhattacharya S (2024) Role of resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist, in managing nonalcoholic steatohepatitis: a systematic review and meta-analysis. Endocr Pract 30:631\u2013638. https:\/\/doi.org\/10.1016\/j.eprac.2024.04.016","journal-title":"Endocr Pract"},{"key":"1574_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"E EaslEaso","year":"2024","unstructured":"EaslEaso E (2024) EASL-EASD-EASO Clinical Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"1574_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/jgh.16874","volume":"40","author":"D Ezhilarasan","year":"2025","unstructured":"Ezhilarasan D (2025) Thyromimetics and MASLD: unveiling the novel molecules beyond resmetirom. J Gastroenterol Hepatol 40:367\u2013378. https:\/\/doi.org\/10.1111\/jgh.16874","journal-title":"J Gastroenterol Hepatol"},{"key":"1574_CR16","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-G\u00f3mez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF (2021) A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH. N Engl J Med 385:1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2036205","journal-title":"N Engl J Med"},{"issue":"225","key":"1574_CR17","first-page":"631","volume":"12","author":"N Garg","year":"2009","unstructured":"Garg N, Rao VM, Gandhi RB, Washburn WN, Koehler K, Malm J (2009) Stable oral pharmaceutical composition containing thyroid hormone receptor agonists. U.S Patent Appl. 12(225):631","journal-title":"U.S Patent Appl."},{"key":"1574_CR18","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","volume":"74","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N (2021) Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology 74:1809\u20131824. https:\/\/doi.org\/10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"1574_CR19","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz008","author":"S Groeneweg","year":"2020","unstructured":"Groeneweg S, Van Geest FS, Peeters RP, Heuer H, Visser WE (2020) Thyroid hormone transporters. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnz008","journal-title":"Endocr Rev"},{"key":"1574_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/10600280241259528","volume":"59","author":"E Guirguis","year":"2025","unstructured":"Guirguis E, Dougherty J, Thornby K, Grace Y, Mack K (2025) Resmetirom: the first food and drug administration-approved medication for nonalcoholic steatohepatitis (NASH). Ann Pharmacother 59:162\u2013173. https:\/\/doi.org\/10.1177\/10600280241259528","journal-title":"Ann Pharmacother"},{"key":"1574_CR21","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.bmcl.2005.02.028","volume":"15","author":"H Haning","year":"2005","unstructured":"Haning H, Woltering M, Mueller U, Schmidt G, Schmeck C, Voehringer V, Kretschmer A, Pernerstorfer J (2005) Novel heterocyclic thyromimetics. Bioorg Med Chem Lett 15:1835\u20131840. https:\/\/doi.org\/10.1016\/j.bmcl.2005.02.028","journal-title":"Bioorg Med Chem Lett"},{"key":"1574_CR22","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1016\/j.bmcl.2007.04.085","volume":"17","author":"H Haning","year":"2007","unstructured":"Haning H, Mueller U, Schmidt G, Schmeck C, Voehringer V, Kretschmer A, Bischoff H (2007) Novel heterocyclic thyromimetics. Part 2. Bioorg Med Chem Lett 17:3992\u20133996. https:\/\/doi.org\/10.1016\/j.bmcl.2007.04.085","journal-title":"Bioorg Med Chem Lett"},{"key":"1574_CR23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","volume":"81","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Dubourg J (2024) Liver biopsy evaluation in MASH drug development: think thrice, act wise. J Hepatol 81:886\u2013894. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.008","journal-title":"J Hepatol"},{"key":"1574_CR24","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/s0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394:2012\u20132024. https:\/\/doi.org\/10.1016\/s0140-6736(19)32517-6","journal-title":"Lancet"},{"key":"1574_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep4.1657","volume":"5","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE, Mccarty K, Frias JP, Taub R, Alkhouri N (2021) Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun 5:573\u2013588. https:\/\/doi.org\/10.1002\/hep4.1657","journal-title":"Hepatol Commun"},{"key":"1574_CR26","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, Bashir MR (2023a) Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 29:2919\u20132928. https:\/\/doi.org\/10.1038\/s41591-023-02603-1","journal-title":"Nat Med"},{"key":"1574_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","volume":"78","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, Bedossa P, Cusi K, Ratziu V, Grouin JM, Moller DE, Fouqueray P (2023b) Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1). J Hepatol 78:914\u2013925. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.004","journal-title":"J Hepatol"},{"key":"1574_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Peric\u00e0s JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"1574_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70025","author":"HT Hashim","year":"2024","unstructured":"Hashim HT, Alhatemi AQM, Riaz S, Al-Ghuraibawi MA, Alabide AS, Saeed H, Sulaiman FA, Alhussain MAA, Shallan MA, Al-Obaidi AD, Saab O, Al-Obaidi H, Hashim AT, Merza N (2024) Unveiling Resmetirom: a systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment. JGH Open. https:\/\/doi.org\/10.1002\/jgh3.70025","journal-title":"JGH Open"},{"key":"1574_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1042\/bj20021509","volume":"369","author":"MJ Holness","year":"2003","unstructured":"Holness MJ, Bulmer K, Smith ND, Sugden MC (2003) Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone. Biochem J 369:687\u2013695. https:\/\/doi.org\/10.1042\/bj20021509","journal-title":"Biochem J"},{"key":"1574_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213714","author":"GS H\u00f6nes","year":"2022","unstructured":"H\u00f6nes GS, Sivakumar RG, Hoppe C, K\u00f6nig J, F\u00fchrer D, Moeller LC (2022) Cell-specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232213714","journal-title":"Int J Mol Sci"},{"key":"1574_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4166\/kjg.2024.048","volume":"83","author":"H Hong","year":"2024","unstructured":"Hong H, Choi J (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. Korean J Gastroenterol 83:253\u2013255. https:\/\/doi.org\/10.4166\/kjg.2024.048","journal-title":"Korean J Gastroenterol"},{"key":"1574_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch M, Roden M, Kahl S (2024) Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease? Metabolism 157:155937. https:\/\/doi.org\/10.1016\/j.metabol.2024.155937","journal-title":"Metabolism"},{"key":"1574_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s41669-022-00370-2","volume":"7","author":"M Javanbakht","year":"2023","unstructured":"Javanbakht M, Fishman J, Moloney E, Rydqvist P, Ansaripour A (2023) Early cost-effectiveness and price threshold analyses of Resmetirom: an investigational treatment for management of nonalcoholic steatohepatitis. Pharmacoecon Open 7:93\u2013110. https:\/\/doi.org\/10.1007\/s41669-022-00370-2","journal-title":"Pharmacoecon Open"},{"key":"1574_CR35","doi-asserted-by":"publisher","first-page":"E3451","DOI":"10.1073\/pnas.1506113113","volume":"113","author":"jul-Rodr\u00edguez L, Contreras-Jurado C","year":"2016","unstructured":"jul-Rodr\u00edguez L, Contreras-Jurado C, Regadera J and Aranda A, (2016) Thyroid hormones inhibit TGF-\u03b2 signaling and attenuate fibrotic responses. Proc Natl Acad Sci U S A 113:E3451-3460. https:\/\/doi.org\/10.1073\/pnas.1506113113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1574_CR36","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1111\/bph.15427","volume":"178","author":"A Kannt","year":"2021","unstructured":"Kannt A, Wohlfart P, Madsen AN, Veidal SS, Feigh M, Schmoll D (2021) Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol 178:2412\u20132423. https:\/\/doi.org\/10.1111\/bph.15427","journal-title":"Br J Pharmacol"},{"key":"1574_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.17925\/ee.2023.19.1.60","volume":"19","author":"G Karim","year":"2023","unstructured":"Karim G, Bansal MB (2023) Resmetirom: an orally administered, small-molecule, liver-directed, \u03b2-selective THR Agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. TouchREVIEWS in Endocrinology 19:60\u201370. https:\/\/doi.org\/10.17925\/ee.2023.19.1.60","journal-title":"TouchREVIEWS in Endocrinology"},{"key":"1574_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/mcg.0000000000002150","volume":"59","author":"E Kaya","year":"2025","unstructured":"Kaya E, Yilmaz Y, Alkhouri N (2025) Clinical insights on Resmetirom. J Clin Gastroenterol 59:412\u2013419. https:\/\/doi.org\/10.1097\/mcg.0000000000002150","journal-title":"J Clin Gastroenterol"},{"key":"1574_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ (2024) Resmetirom: first approval. Drugs 84:729\u2013735. https:\/\/doi.org\/10.1007\/s40265-024-02045-0","journal-title":"Drugs"},{"key":"1574_CR40","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"MJ Kelly","year":"2014","unstructured":"Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, So SS, Thakkar K, Qian YM, Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J (2014) Discovery of 2\u20133,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl -3,5-dioxo-2,3,4,5-tetrahydro 1,2,4 triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia. J Med Chem 57:3912\u20133923. https:\/\/doi.org\/10.1021\/jm4019299","journal-title":"J Med Chem"},{"key":"1574_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010306","author":"T Khare","year":"2025","unstructured":"Khare T, Liu K, Chilambe LO, Khare S (2025) NAFLD and NAFLD related HCC: emerging treatments and clinical trials. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26010306","journal-title":"Int J Mol Sci"},{"key":"1574_CR42","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.14309\/ajg.0000000000000654","volume":"115","author":"D Kim","year":"2020","unstructured":"Kim D, Vazquez-Montesino LM, Escober JA, Fernandes CT, Cholankeril G, Loomba R, Harrison SA, Younossi ZM, Ahmed A (2020) Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality. Am J Gastroenterol 115:1496\u20131504. https:\/\/doi.org\/10.14309\/ajg.0000000000000654","journal-title":"Am J Gastroenterol"},{"key":"1574_CR43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","volume":"29","author":"SA Kliewer","year":"2019","unstructured":"Kliewer SA, Mangelsdorf DJ (2019) A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab 29:246\u2013253. https:\/\/doi.org\/10.1016\/j.cmet.2019.01.004","journal-title":"Cell Metab"},{"key":"1574_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47030154","author":"E Knezovi\u0107","year":"2025","unstructured":"Knezovi\u0107 E, Hefer M, Bla\u017eanovi\u0107 S, Petrovi\u0107 A, Tomi\u010di\u0107 V, Srb N, Kirner D, Smoli\u0107 R, Smoli\u0107 M (2025) Drug pipeline for MASLD: what can be learned from the successful story of Resmetirom. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47030154","journal-title":"Curr Issues Mol Biol"},{"key":"1574_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ani12070939","author":"Y Kong","year":"2022","unstructured":"Kong Y, Zhao C, Tan P, Liu S, Huang Y, Zeng F, Ma P, Guo Y, Zhao B, Wang J (2022) FGF21 reduces lipid accumulation in bovine hepatocytes by enhancing lipid oxidation and reducing lipogenesis via AMPK signaling. Animals. https:\/\/doi.org\/10.3390\/ani12070939","journal-title":"Animals"},{"key":"1574_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70003","volume":"55","author":"LAM Konings","year":"2025","unstructured":"Konings LAM, Miguela\u00f1ez-Matute L, Boeren AMP, Van De Luitgaarden IAT, Dirksmeier F, De Knegt RJ, Tushuizen ME, Grobbee DE, Holleboom AG, Cabezas MC (2025) Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review. Eur J Clin Invest 55:e70003. https:\/\/doi.org\/10.1111\/eci.70003","journal-title":"Eur J Clin Invest"},{"key":"1574_CR47","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1530\/ec-18-0499","volume":"7","author":"C Krause","year":"2018","unstructured":"Krause C, Grohs M, El Gammal AT, Wolter S, Lehnert H, Mann O, Mittag J, Kirchner H (2018) Reduced expression of thyroid hormone receptor \u03b2 in human nonalcoholic steatohepatitis. Endocr Connect 7:1448\u20131456. https:\/\/doi.org\/10.1530\/ec-18-0499","journal-title":"Endocr Connect"},{"key":"1574_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103034","volume":"18","author":"MS Kuchay","year":"2024","unstructured":"Kuchay MS, Isaacs S, Misra A (2024) Intrahepatic hypothyroidism in MASLD: role of liver-specific thyromimetics including resmetirom. Diabetes Metab Syndr 18:103034. https:\/\/doi.org\/10.1016\/j.dsx.2024.103034","journal-title":"Diabetes Metab Syndr"},{"key":"1574_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/mcg.0000000000002140","volume":"59","author":"BP Lam","year":"2025","unstructured":"Lam BP, Bartholomew J, Bau S, Gilles H, Keller A, Moore A, Nader K, Richards L, Henry L, Younossi ZM (2025) Focused recommendations for the management of metabolic dysfunction-associated steatohepatitis (MASH) by advanced practice providers in the United States. J Clin Gastroenterol 59:298\u2013309. https:\/\/doi.org\/10.1097\/mcg.0000000000002140","journal-title":"J Clin Gastroenterol"},{"key":"1574_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mce.2014.02.003","volume":"388","author":"JA Lammel Lindemann","year":"2014","unstructured":"Lammel Lindemann JA, Angajala A, Engler DA, Webb P, Ayers SD (2014) Thyroid hormone induction of human cholesterol 7 alpha-hydroxylase (Cyp7a1) in vitro. Mol Cell Endocrinol 388:32\u201340. https:\/\/doi.org\/10.1016\/j.mce.2014.02.003","journal-title":"Mol Cell Endocrinol"},{"key":"1574_CR51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","volume":"116","author":"JI Lee","year":"2021","unstructured":"Lee JI, Lee HW, Lee KS, Lee HS, Park JY (2021) Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Am J Gastroenterol 116:116\u2013124. https:\/\/doi.org\/10.14309\/ajg.0000000000000845","journal-title":"Am J Gastroenterol"},{"key":"1574_CR52","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2147\/dddt.S310163","volume":"15","author":"J Li","year":"2021","unstructured":"Li J, Guo C, Wu J (2021a) The agonists of peroxisome proliferator-activated receptor-\u03b3 for liver fibrosis. Drug des Devel Ther 15:2619\u20132628. https:\/\/doi.org\/10.2147\/dddt.S310163","journal-title":"Drug des Devel Ther"},{"key":"1574_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100134","volume":"62","author":"R Li","year":"2021","unstructured":"Li R, Palmiotti A, De Vries HD, Hovingh MV, Koehorst M, Mulder NL, Zhang Y, Kats K, Bloks VW, Fu J, Verkade HJ, De Boer JF, Kuipers F (2021b) Low production of 12\u03b1-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70(-\/-) mice by reducing fat absorption. J Lipid Res 62:100134. https:\/\/doi.org\/10.1016\/j.jlr.2021.100134","journal-title":"J Lipid Res"},{"key":"1574_CR54","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagstr\u00f6m H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Dur\u00e1n R, Sanyal AJ, De L\u00e9dinghen V, Newsome PN, Fan JG, Cast\u00e9ra L, Lai M, Harrison SA, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, De Saint-Loup M, Llop E, Teh KK, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gomez M, Kim SU, Wong VW (2024) Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA 331:1287\u20131297. https:\/\/doi.org\/10.1001\/jama.2024.1447","journal-title":"JAMA"},{"key":"1574_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5753039","author":"L Liu","year":"2017","unstructured":"Liu L, Yu Y, Zhao M, Zheng D, Zhang X, Guan Q, Xu C, Gao L, Zhao J, Zhang H (2017) Benefits of levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients. Int J Endocrinol. https:\/\/doi.org\/10.1155\/2017\/5753039","journal-title":"Int J Endocrinol"},{"key":"1574_CR56","doi-asserted-by":"publisher","first-page":"1534628","DOI":"10.3389\/fphar.2025.1534628","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Zhao X, Wang X, Zhou Q (2025) Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-vigiaccess database. Front Pharmacol 16:1534628. https:\/\/doi.org\/10.3389\/fphar.2025.1534628","journal-title":"Front Pharmacol"},{"key":"1574_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240338","volume":"15","author":"XG Luong","year":"2020","unstructured":"Luong XG, Stevens SK, Jekle A, Lin TI, Gupta K, Misner D, Chanda S, Mukherjee S, Williams C, Stoycheva A, Blatt LM, Beigelman LN, Symons JA, Raboisson P, Mcgowan D, Vandyck K, Deval J (2020) Regulation of gene transcription by thyroid hormone receptor \u03b2 agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS ONE 15:e0240338. https:\/\/doi.org\/10.1371\/journal.pone.0240338","journal-title":"PLoS ONE"},{"key":"1574_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312797","author":"M Mavromati","year":"2021","unstructured":"Mavromati M, Jornayvaz FR (2021) Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222312797","journal-title":"Int J Mol Sci"},{"key":"1574_CR59","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1097\/ms9.0000000000002314","volume":"86","author":"S Mazhar","year":"2024","unstructured":"Mazhar S, Azhar A, Khan A, Shakil G, Kumari S, Devi D, Jawad S (2024) Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis. Ann Med Surg (Lond) 86:5447\u20135454. https:\/\/doi.org\/10.1097\/ms9.0000000000002314","journal-title":"Ann Med Surg (Lond)"},{"key":"1574_CR60","doi-asserted-by":"publisher","DOI":"10.1155\/ije\/6430023","volume":"2025","author":"AM Mousa","year":"2025","unstructured":"Mousa AM, Mahmoud M, Alshuraiaan GM (2025) Resmetirom: the first disease-specific treatment for MASH. Int J Endocrinol 2025:6430023. https:\/\/doi.org\/10.1155\/ije\/6430023","journal-title":"Int J Endocrinol"},{"key":"1574_CR61","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","volume":"155","author":"G Musso","year":"2018","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R (2018) Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology 155:282-302.e288. https:\/\/doi.org\/10.1053\/j.gastro.2018.06.031","journal-title":"Gastroenterology"},{"key":"1574_CR62","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P (2023) Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol 79:1557\u20131565. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.033","journal-title":"J Hepatol"},{"key":"1574_CR63","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"1574_CR64","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA, Bansal MB, Alkhouri N, Loomba R, Sanyal AJ, Rinella ME (2024) Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol 22:2367\u20132377. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1574_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70056","volume":"45","author":"G Pennisi","year":"2025","unstructured":"Pennisi G, Di Maria G, Enea M, Vaccaro M, Celsa C, Antonucci M, Ciancimino G, Ciccioli C, Infantino G, La Mantia C, Tulone A, Di Marco V, Camm\u00e0 C, Petta S (2025) A markov model unveiling the impact of Resmetirom on the natural history of MASLD patients: a sistematic review and meta-analysis. Liver Int 45:e70056. https:\/\/doi.org\/10.1111\/liv.70056","journal-title":"Liver Int"},{"key":"1574_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15930","author":"S Petta","year":"2024","unstructured":"Petta S, Targher G, Romeo S, Pajvani UB, Zheng MH, Aghemo A, Valenti LVC (2024) The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int. https:\/\/doi.org\/10.1111\/liv.15930","journal-title":"Liver Int"},{"key":"1574_CR67","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VWS, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397:2212\u20132224. https:\/\/doi.org\/10.1016\/s0140-6736(20)32511-3","journal-title":"Lancet"},{"key":"1574_CR68","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/14656566.2024.2374463","volume":"25","author":"T Puengel","year":"2024","unstructured":"Puengel T, Tacke F (2024) Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today? Expert Opin Pharmacother 25:1249\u20131263. https:\/\/doi.org\/10.1080\/14656566.2024.2374463","journal-title":"Expert Opin Pharmacother"},{"key":"1574_CR69","doi-asserted-by":"publisher","first-page":"E884","DOI":"10.1152\/ajpendo.90438.2008","volume":"295","author":"A Radenne","year":"2008","unstructured":"Radenne A, Akpa M, Martel C, Sawadogo S, Mauvoisin D, Mounier C (2008) Hepatic regulation of fatty acid synthase by insulin and T3: evidence for T3 genomic and nongenomic actions. Am J Physiol Endocrinol Metab 295:E884-894. https:\/\/doi.org\/10.1152\/ajpendo.90438.2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1574_CR70","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1097\/ms9.0000000000002195","volume":"86","author":"A Raja","year":"2024","unstructured":"Raja A, Subhash Sagar R, Saeed S, Zia Ul Haq A, Khan O, Dileep Bhimani P, Raja S, Deepak F, Ahmed M, Ashir Shafique M, Saqlain Mustafa M, Sohaib Asghar M, Sharma V (2024) Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis. Ann Med Surg (Lond) 86:4130\u20134138. https:\/\/doi.org\/10.1097\/ms9.0000000000002195","journal-title":"Ann Med Surg (Lond)"},{"key":"1574_CR71","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","volume":"82","author":"V Ratziu","year":"2025","unstructured":"Ratziu V, Scanlan TS, Bruinstroop E (2025) Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). J Hepatol 82:375\u2013387. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.018","journal-title":"J Hepatol"},{"key":"1574_CR72","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000670","author":"N Ravela","year":"2025","unstructured":"Ravela N, Shackelford P, Blessing N, Yoder L, Chalasani N, Samala N (2025) Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting. Hepatol Commun. https:\/\/doi.org\/10.1097\/hc9.0000000000000670","journal-title":"Hepatol Commun"},{"key":"1574_CR73","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"M Roth","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260\u20131287. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01724.x","journal-title":"Br J Pharmacol"},{"key":"1574_CR74","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Shankar SS, Yates KP, Bolognese J, Daly E, Dehn CA, Neuschwander-Tetri B, Kowdley K, Vuppalanchi R, Behling C, Tonascia J, Samir A, Sirlin C, Sherlock SP, Fowler K, Heymann H, Kamphaus TN, Loomba R, Calle RA (2023) Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med 29:2656\u20132664. https:\/\/doi.org\/10.1038\/s41591-023-02539-6","journal-title":"Nat Med"},{"key":"1574_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.70002","volume":"18","author":"R Shi","year":"2025","unstructured":"Shi R, Chai K, Wang H, Zhou J, Yang S, Li J, Qiao C, Sheng X, Zhang X, Wu J (2025) Clinical assessment of common medications for nonalcoholic fatty liver disease: a systematic review and Bayesian network meta-analysis. J Evid Based Med 18:e70002. https:\/\/doi.org\/10.1111\/jebm.70002","journal-title":"J Evid Based Med"},{"key":"1574_CR76","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s42255-024-00986-0","volume":"6","author":"RA Sinha","year":"2024","unstructured":"Sinha RA, Yen PM (2024) Metabolic messengers: thyroid hormones. Nat Metab 6:639\u2013650. https:\/\/doi.org\/10.1038\/s42255-024-00986-0","journal-title":"Nat Metab"},{"key":"1574_CR77","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/15548627.2015.1061849","volume":"11","author":"RA Sinha","year":"2015","unstructured":"Sinha RA, Singh BK, Zhou J, Wu Y, Farah BL, Ohba K, Lesmana R, Gooding J, Bay BH, Yen PM (2015) Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. Autophagy 11:1341\u20131357. https:\/\/doi.org\/10.1080\/15548627.2015.1061849","journal-title":"Autophagy"},{"key":"1574_CR78","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrendo.2018.10","volume":"14","author":"RA Sinha","year":"2018","unstructured":"Sinha RA, Singh BK, Yen PM (2018) Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol 14:259\u2013269. https:\/\/doi.org\/10.1038\/nrendo.2018.10","journal-title":"Nat Rev Endocrinol"},{"key":"1574_CR79","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1089\/thy.2018.0664","volume":"29","author":"RA Sinha","year":"2019","unstructured":"Sinha RA, Bruinstroop E, Singh BK, Yen PM (2019) Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid 29:1173\u20131191. https:\/\/doi.org\/10.1089\/thy.2018.0664","journal-title":"Thyroid"},{"key":"1574_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41575-024-00991-4","volume":"22","author":"RA Sinha","year":"2025","unstructured":"Sinha RA, Bruinstroop E, Yen PM (2025) Actions of thyroid hormones and thyromimetics on the liver. Nat Rev Gastroenterol Hepatol 22:9\u201322. https:\/\/doi.org\/10.1038\/s41575-024-00991-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1574_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001254","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R (2025) Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology. https:\/\/doi.org\/10.1097\/hep.0000000000001254","journal-title":"Hepatology"},{"key":"1574_CR82","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","volume":"73","author":"EP Stahl","year":"2019","unstructured":"Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol 73:948\u2013963. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.050","journal-title":"J Am Coll Cardiol"},{"key":"1574_CR83","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0169-409x(01)00099-0","volume":"48","author":"GA Stephenson","year":"2001","unstructured":"Stephenson GA, Forbes RA, Reutzel-Edens SM (2001) Characterization of the solid state: quantitative issues. Adv Drug Deliv Rev 48:67\u201390. https:\/\/doi.org\/10.1016\/s0169-409x(01)00099-0","journal-title":"Adv Drug Deliv Rev"},{"key":"1574_CR84","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1038\/s41401-024-01303-x","volume":"45","author":"K Sun","year":"2024","unstructured":"Sun K, Zhu NL, Huang SL, Qu H, Gu YP, Qin L, Liu J, Leng Y (2024) A new mechanism of thyroid hormone receptor \u03b2 agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles. Acta Pharmacol Sin 45:2134\u20132148. https:\/\/doi.org\/10.1038\/s41401-024-01303-x","journal-title":"Acta Pharmacol Sin"},{"key":"1574_CR85","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke F, Pungel T, Loomba R, Friedman SL (2023) An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol 79:552\u2013566. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.038","journal-title":"J Hepatol"},{"key":"1574_CR86","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/meg.0000000000002892","volume":"37","author":"M Talha","year":"2025","unstructured":"Talha M, Ali MH, Nadeem ZA, Akram U, Saravanan PB, Khalid MHA (2025) Efficacy and safety of resmetirom for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis. Eur J Gastroenterol Hepatol 37:247\u2013256. https:\/\/doi.org\/10.1097\/meg.0000000000002892","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1574_CR87","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","volume":"230","author":"R Taub","year":"2013","unstructured":"Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin M-C, Tardif J-C (2013) Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist. Atherosclerosis 230:373\u2013380. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.07.056","journal-title":"Atherosclerosis"},{"key":"1574_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2022.120857","author":"GX Tian","year":"2023","unstructured":"Tian GX, Luo Y, Lou BX, Sui JJ, Qin XL, Shen YH, Zhu XY, Lu J (2023) Screening, packing systematics, Hansen solubility parameters and desolvation of resmetirom (MGL-3196) solvates. J Mol Liq. https:\/\/doi.org\/10.1016\/j.molliq.2022.120857","journal-title":"J Mol Liq"},{"key":"1574_CR89","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2003.10.008","volume":"40","author":"SR Vavricka","year":"2004","unstructured":"Vavricka SR, Jung D, Fried M, Gr\u00fctzner U, Meier PJ, Kullak-Ublick GA (2004) The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3\u03b2 in hepatocellular carcinoma. J Hepatol 40:212\u2013218. https:\/\/doi.org\/10.1016\/j.jhep.2003.10.008","journal-title":"J Hepatol"},{"key":"1574_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914605","author":"P Vidal-Cevallos","year":"2023","unstructured":"Vidal-Cevallos P, Gall SMB, Uribe M, Ch\u00e1vez-Tapia NC (2023) Understanding the relationship between nonalcoholic fatty liver disease and thyroid disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241914605","journal-title":"Int J Mol Sci"},{"key":"1574_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065843","author":"X Wang","year":"2023","unstructured":"Wang X, Wang L, Geng L, Tanaka N, Ye B (2023) Resmetirom ameliorates NASH-model mice by suppressing STAT3 and NF-\u03baB signaling pathways in an RGS5-dependent manner. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065843","journal-title":"Int J Mol Sci"},{"key":"1574_CR92","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41401-024-01466-7","volume":"46","author":"SW Wong","year":"2025","unstructured":"Wong SW, Yang YY, Chen H, Xie L, Shen XZ, Zhang NP, Wu J (2025) New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024. Acta Pharmacol Sin 46:1145\u20131155. https:\/\/doi.org\/10.1038\/s41401-024-01466-7","journal-title":"Acta Pharmacol Sin"},{"key":"1574_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2025.127568","volume":"287","author":"C Yang","year":"2025","unstructured":"Yang C, Luo Y, Sun W, Liu X, Zhu X (2025) Comparison of resmetirom quantative analysis in API and formulation models based on PXRD, FTIR and Raman scanning imaging combined with univariate and multivariate analyses. Talanta 287:127568. https:\/\/doi.org\/10.1016\/j.talanta.2025.127568","journal-title":"Talanta"},{"key":"1574_CR94","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA (2022) Hepatic Fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol 20:1354-1361.e1357. https:\/\/doi.org\/10.1016\/j.cgh.2021.07.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1574_CR95","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/hep.0000000000001084","volume":"81","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Stepanova M, Racila A, Henry L, Labriola D, Taub R, Nader F (2025) Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology 81:1318\u20131327. https:\/\/doi.org\/10.1097\/hep.0000000000001084","journal-title":"Hepatology"},{"key":"1574_CR96","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1074\/jbc.M005894200","volume":"276","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Yin L, Hillgartner FB (2001) Thyroid hormone stimulates acetyl-coA carboxylase-alpha transcription in hepatocytes by modulating the composition of nuclear receptor complexes bound to a thyroid hormone response element. J Biol Chem 276:974\u2013983. https:\/\/doi.org\/10.1074\/jbc.M005894200","journal-title":"J Biol Chem"},{"key":"1574_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.008","author":"YH Zhang","year":"2024","unstructured":"Zhang YH, Xie R, Dai CS, Gao HW, Zhou G, Qi TT, Wang WY, Wang H, Cui YM (2024) Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.008","journal-title":"J Hepatol"},{"key":"1574_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100018","volume":"77","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lau HC, Yu J (2025a) Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: current and emerging therapeutic options. Pharmacol Rev 77:100018. https:\/\/doi.org\/10.1016\/j.pharmr.2024.100018","journal-title":"Pharmacol Rev"},{"key":"1574_CR99","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","volume":"37","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zheng MH, Liu D, Lin Y, Song SJ, Chu ES, Liu D, Singh S, Berman M, Lau HC, Gou H, Wong GL, Zhang N, Yuan HY, Loomba R, Wong VW, Yu J (2025b) A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. Cell Metab 37:59-68.e53. https:\/\/doi.org\/10.1016\/j.cmet.2024.10.008","journal-title":"Cell Metab"},{"key":"1574_CR100","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1111\/dom.16348","volume":"27","author":"J Zhong","year":"2025","unstructured":"Zhong J, Cai Z, Zhu G, Zhang J (2025) Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: a network meta-analysis. Diabetes Obes Metab 27:3309\u20133323. https:\/\/doi.org\/10.1111\/dom.16348","journal-title":"Diabetes Obes Metab"},{"key":"1574_CR101","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/apt.18062","volume":"60","author":"XD Zhou","year":"2024","unstructured":"Zhou XD, Liu WY, Targher G, Byrne CD, Zheng MH (2024) Letter: drug interaction in resmetirom times. Aliment Pharmacol Ther 60:533\u2013534. https:\/\/doi.org\/10.1111\/apt.18062","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01574-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01574-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01574-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:35:30Z","timestamp":1764952530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01574-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":101,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1574"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01574-w","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}